S-type Pyocins for Pulmonary Treatment of Bacterial Respiratory Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics are ineffective against Gram-negative pathogens like Pseudomonas aeruginosa due to antibiotic resistance and the impermeable outer membrane, leading to limited therapeutic options for bacterial respiratory infections, particularly in patients with cystic fibrosis and other respiratory conditions.
Innovation Solution
The use of S-type pyocins, which are bacterially-derived protein antibiotics, is explored for pulmonary administration to target and reduce bacterial loads in respiratory infections without triggering an immune response, utilizing their targeting and effector portions to cross the outer membrane and exert cytotoxic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat Gram-negative bacterial infections, then treatment is attempted, but the antibiotics are ineffective due to antibiotic resistance and impermeable outer membrane
Solution Approach 1:
The patent changes the fundamental parameter of the therapeutic agent from conventional small-molecule antibiotics to bacteriocin-based protein antibiotics (pyocins). These pyocins have evolved mechanisms to specifically target Gram-negative bacteria by parasitizing existing nutrient uptake pathways, thereby overcoming the outer membrane impermeability barrier that renders conventional antibiotics ineffective.
Solution Approach 2:
The patent employs pyocins as intermediary agents that exploit the bacteria's own nutrient uptake systems as mediators to deliver cytotoxic activity into the bacterial cell. This intermediary approach allows the therapeutic agent to use the target bacteria's metabolic pathways against them, bypassing the need to directly penetrate the outer membrane with the active therapeutic component.
2Reliability
If bacterially-derived protein antibiotics (pyocins) are administered systemically, then potent narrow-spectrum activity against target bacteria is achieved, but immune response is triggered that could be damaging to respiratory tissue
Solution Approach 1:
The patent applies local quality by delivering the pyocin therapeutic agent directly to the site of infection (respiratory tract) via inhalation rather than systemic administration. This localized delivery ensures high concentration of the agent at the target site while minimizing exposure to the immune system in other parts of the body, thereby reducing the risk of immune-mediated tissue damage.
Solution Approach 2:
The patent extracts only the essential cytotoxic functional domains from the complete pyocin structure to create truncated variants. These truncated pyocins retain the ability to kill target bacteria but have reduced immunogenicity, effectively separating the therapeutic function from the harmful immune-triggering properties.
3Object-affected harmful factors
If truncated pyocin variants are used to reduce immunogenicity, then immune response is minimized, but manufacturing complexity increases due to need to identify and characterize multiple variants
Solution Approach 1:
The patent segments the pyocin molecule into distinct functional domains (targeting domain and cytotoxic effector domain) and selectively truncates the N-terminal targeting region while preserving the C-terminal effector region. This systematic segmentation approach creates a series of truncated variants with predictable properties, simplifying the manufacturing and characterization process compared to testing random fragments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
S-type pyocins demonstrate significant reduction in bacterial loads in the lungs without causing tissue damage or immune response, offering a potent and effective treatment for bacterial respiratory infections, including those resistant to conventional antibiotics, with pyocin S5 showing particular efficacy in reducing bacterial counts by several orders of magnitude.
Implementation Method 1
These bacteriocins have evolved to efficiently cross the Gram-negative outer membrane through the parasitisation of existing active nutrient uptake pathways
Implementation Method 2
The cellular targets of these protein antibiotics are highly conserved, with cytotoxic activity most commonly taking the form of a nuclease activity targeting DNA, rRNA or tRNA
Implementation Method 3
or a pore-forming activity targeting the cytoplasmic membrane
Data Source
AI summary
The treatment of bacterial respiratory infections using bacterially-originating antibiotics known as pyocins are provided. In particular, S-type pyocins are administered by pulmonary administration for the treatment of bacterial infections such as Pseudomonas aeruginosa infections. Methods of using S-type pyocin proteins, particularly those comprising an S2, SD2, S5 or AP41 targeting portion or an S2, SD2, S5 or AP41 effector portion are provided.